Meet The Scientists
Charles Vite
VS, DVM, PhD
Christin Davidson
PhD
Stephanie Cologna
PhD
Mark Schultz
PhD
Andrew Lieberman
MD, PhD
Forbes D. Porter
PhD, MD
Current and past scientific collaborators in the NPC and broader scientific community
- David Begley, King’s College London: CNS distribution of hydroxypropyl-beta-cyclodextrin (HPBCD)
- Ashley Bush, University of Melbourne: Measurement of metals in NPC1 mouse tissues
- Keith Duncan, University of Michigan: HPBCD-induced ototoxicity
- Larry Goldstein, University of California San Diego: Evaluation of compounds that improve mitochondrial viability
- Paul Helquist and Olaf Wiest, University of Notre Dame; Fred Maxfield, Cornell Weill; Ed Holson, Broad Institute: Evaluation of HDAC inhibitors for treatment of NPC1 disease
- Danny Manor, Case Western Reserve University: Evaluation of tocopherol processing
- Ralph Nixon, Nathan S. Kline Institute: Similarities between NPC and Alzheimer mouse models
- Paulina Ordonez, University of California San Diego: Evaluation of mitoprotective agents
- Bill Pavan, National Human Genome Research Institute: Effect of NAC on NPC1 disease progression and gene therapy in NPC1 disease
- Frances Platt, University of Oxford; Mario Cortina-Borja, University College London: Analysis of biomarkers
- Heiko Runz, University of Heidelberg: Effect of TMEM97 inhibition in vivo
- Lajos Szente, CycloLab: Cyclodextrin biochemistry and mechanism of action
- Wei Zheng, National Center for Advancing Translational Sciences: Examination of combined tocopherol/cyclodextrin therapy
- Charles Venditti and Bill Pavan, National Human Genome Research Institute: Gene therapy in NPC1 disease
- Vytautas Verselis and Helmuth Sanchez, Albert Einstein College of Medicine: Effect of cyclodextrin on hearing and hair cells in an NPC1 mouse model
NPC Research
Interested in learning more about NPC? Put your science cap on and explore some of the different topics in NPC research!
Collaboration at Work
- David Begley, King’s College London: CNS distribution of hydroxypropyl-beta-cyclodextrin (HPBCD)
- Ashley Bush, University of Melbourne: Measurement of metals in NPC1 mouse tissues
- Keith Duncan, University of Michigan: HPBCD-induced ototoxicity
- Larry Goldstein, University of California San Diego: Evaluation of compounds that improve mitochondrial viability
- Paul Helquist and Olaf Wiest, University of Notre Dame; Fred Maxfield, Cornell Weill; Ed Holson, Broad Institute: Evaluation of HDAC inhibitors for treatment of NPC1 disease
- Danny Manor, Case Western Reserve University: Evaluation of tocopherol processing
- Ralph Nixon, Nathan S. Kline Institute: Similarities between NPC and Alzheimer mouse models
- Paulina Ordonez, University of California San Diego: Evaluation of mitoprotective agents
- Bill Pavan, National Human Genome Research Institute: Effect of NAC on NPC1 disease progression and gene therapy in NPC1 disease
- Frances Platt, University of Oxford; Mario Cortina-Borja, University College London: Analysis of biomarkers
- Heiko Runz, University of Heidelberg: Effect of TMEM97 inhibition in vivo
- Lajos Szente, CycloLab: Cyclodextrin biochemistry and mechanism of action
- Wei Zheng, National Center for Advancing Translational Sciences: Examination of combined tocopherol/cyclodextrin therapy
- Charles Venditti and Bill Pavan, National Human Genome Research Institute: Gene therapy in NPC1 disease
- Vytautas Verselis and Helmuth Sanchez, Albert Einstein College of Medicine: Effect of cyclodextrin on hearing and hair cells in an NPC1 mouse model
Collaboration at Work
Therapeutic Advancements
Diagnostic and Biomarker Advancements
Exciting Basic Research
Origins of Cyclodextrin as a Therapy for NPC disease
Tiger and John are NPC1 heterozygote cats. Upon retirement from status as breeder males, both cats were adopted from the Niemann-Pick C feline colony by a member of the NPC community.
Share This Content